1. Home
  2. DFNS vs CPIX Comparison

DFNS vs CPIX Comparison

Compare DFNS & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFNS

T3 Defense Inc. Common Stock

N/A

Current Price

$1.44

Market Cap

67.1M

ML Signal

N/A

Logo Cumberland Pharmaceuticals Inc.

CPIX

Cumberland Pharmaceuticals Inc.

N/A

Current Price

$3.36

Market Cap

73.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DFNS
CPIX
Founded
2013
1999
Country
United States
United States
Employees
15
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.1M
73.6M
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
DFNS
CPIX
Price
$1.44
$3.36
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.4M
140.2K
Earning Date
01-01-0001
06-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.70
EPS
N/A
N/A
Revenue
N/A
$42,010,949.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.75
52 Week Low
$1.51
$1.85
52 Week High
$2.68
$6.27

Technical Indicators

Market Signals
Indicator
DFNS
CPIX
Relative Strength Index (RSI) 34.77 37.08
Support Level N/A $2.78
Resistance Level $2.56 $3.80
Average True Range (ATR) 0.26 0.30
MACD -0.06 -0.09
Stochastic Oscillator 3.00 3.47

Price Performance

Historical Comparison
DFNS
CPIX

About DFNS T3 Defense Inc. Common Stock

T3 Defense Inc is a world-wide aerospace and defense federated holding company focused on acquiring and operating mission-critical defense businesses embedded at critical chokepoints of long-cycle national security programs. Through disciplined M&A, centralized capital and ideas, and decentralized operating autonomy, it aims to build an asymmetric edge by strengthening critical defense capabilities and compounding long-term value.

About CPIX Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

Share on Social Networks: